Natixis Allogene Therapeutics, Inc. Transaction History
Natixis
- $17.6 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding ALLO
# of Institutions
163Shares Held
134MCall Options Held
59.4KPut Options Held
113K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$39.1 Million1.25% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$34.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.33MShares$17.4 Million0.0% of portfolio
-
State Street Corp Boston, MA7.01MShares$14.7 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$14.4 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $301M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...